T-cell kinetics
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . |
|---|---|---|---|---|---|
| Peak lymphocyte per µL | 7820 (day +8) | 600 (day 14) | 6100 (day +8) | 3258 (day +8) | 1420 (day +9) |
| Trough lymphocyte per µL | 460 (day +11) | 100 (day 18) | 310 (day +13) | 390 (day +13) | 410 (day +12) |
| Peak CD3 count per µL | Not done; 2364 (day +9) | NA | 5520 (day +8) | 3082 (day +8) | 1420 (day +9) |
| Peak CD4 count per µL | Not done; 252 (day +9) | NA | 1656 (day +9) | 2179 (day +8) | 840 (day +9) |
| Peak CD8 count per µL | Not done; 2052 (day +9) | NA | 3983 (day +8) | 1021 (day +8) | 584 (day +10) |
| CD8/CD4 ratio | 5.86 (day +9) | NA | 2.84 (day +8) | 0.46 (day +8) | 0.69 (day +9) |
| 1.1 (day +28) | 0.43 (day+13) | 1.02 (day+12) | 4.9 (day+11) | ||
| Magnitude of expansion | 123-fold | NA | 84-fold | 48-fold | 21-fold |
| Chimerism during T-cell expansion | 100% donor (day +9) | NA | 100% donor (day +8) | 100% donor (day +8) | 100% donor (day +9) |
| Neutrophils >0.5 × 103/µL | Day +19 | Day +12 | Day +14 | Day +12 | Day +27 |
| Platelets >20 × 103/µL | Day +42 | Transfusion dependent | Day +58 | Day +34 | Day +46 |
| Cessation of ciclosporin | Day +33 | NA | Day +33 | Day +76 | Day +44 |
| CMV/ADV/EBV reactivation | None | None | None | None | None |
| Survival | Remains in remission 40 mo posttransplantation | Died of venoocclusive disease and multiorgan failure on day +24 | Remains in remission 31 mo posttransplantation | Remains in remission 20 mo posttransplantation | Remains in remission 14 mo posttransplantation |
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . |
|---|---|---|---|---|---|
| Peak lymphocyte per µL | 7820 (day +8) | 600 (day 14) | 6100 (day +8) | 3258 (day +8) | 1420 (day +9) |
| Trough lymphocyte per µL | 460 (day +11) | 100 (day 18) | 310 (day +13) | 390 (day +13) | 410 (day +12) |
| Peak CD3 count per µL | Not done; 2364 (day +9) | NA | 5520 (day +8) | 3082 (day +8) | 1420 (day +9) |
| Peak CD4 count per µL | Not done; 252 (day +9) | NA | 1656 (day +9) | 2179 (day +8) | 840 (day +9) |
| Peak CD8 count per µL | Not done; 2052 (day +9) | NA | 3983 (day +8) | 1021 (day +8) | 584 (day +10) |
| CD8/CD4 ratio | 5.86 (day +9) | NA | 2.84 (day +8) | 0.46 (day +8) | 0.69 (day +9) |
| 1.1 (day +28) | 0.43 (day+13) | 1.02 (day+12) | 4.9 (day+11) | ||
| Magnitude of expansion | 123-fold | NA | 84-fold | 48-fold | 21-fold |
| Chimerism during T-cell expansion | 100% donor (day +9) | NA | 100% donor (day +8) | 100% donor (day +8) | 100% donor (day +9) |
| Neutrophils >0.5 × 103/µL | Day +19 | Day +12 | Day +14 | Day +12 | Day +27 |
| Platelets >20 × 103/µL | Day +42 | Transfusion dependent | Day +58 | Day +34 | Day +46 |
| Cessation of ciclosporin | Day +33 | NA | Day +33 | Day +76 | Day +44 |
| CMV/ADV/EBV reactivation | None | None | None | None | None |
| Survival | Remains in remission 40 mo posttransplantation | Died of venoocclusive disease and multiorgan failure on day +24 | Remains in remission 31 mo posttransplantation | Remains in remission 20 mo posttransplantation | Remains in remission 14 mo posttransplantation |